Lantern Pharma Receives Notice Of Allowance From U.S. Patent And Trademark Office For 'Methods For The Treatment Of Solid Tumor Cancers Using Illudins And Biomarkers'
Lantern Pharma, Inc.
Lantern Pharma, Inc. LTRN | 0.00 |
The United States Patent and Trademark Office has issued Lantern Biopharma a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers."
The allowed claims cover methods of selecting and treating patients with ovarian, primary liver, kidney, or thyroid cancer with LP-184 (zirdafulven) based on measured elevated expression of each of three genes — PTGR1, PTPN14, and ASPH — in a patient tumor sample.